acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone here is free to speculate on what they believe will happen today, tomorrow, next week,next month, or next year.
The validity of the speculation at the time of the speculation only exists to the extent that others give it some degree of credibility.
I don't think anyone should make an investment decision based on any opinion or speculative post from an IHub or Yahoo stock board.
I think the share price should be in the .12-.15 range currently. That is my opinion. The market obviously begs to differ.
Interesting months ahead.
Twitter: @AmarantusBio .... 9,971 followers.
It's my understanding that the numbers have improved over these:
92% Sensitivity - 91% Specificity
http://www.sec.gov/Archives/edgar/data/1424812/000114420413049849/v354630_ex99-2.htm
Twitter: @AmarantusBio .... 9,965 followers
Good overview of the company:
http://content.stockpr.com/amarantus/media/3b975cd360749a34eb202bd4c0121792.pdf
If you don't know the difference between $5.00 and $2.00 then I have a stack of $2.00 bills that I'll trade with you.
Have a great day!!!
Something to read today:
http://www.elks.org/SharedElksOrg/lodges/files/0948_SoldiersPoem.pdf
Your statement:
"Only folks on here are praying and hoping and expecting that the pps will reach $5 on its own this year."
Is a blatant falsehood. I don't think there's one individual here that expects the share price to go to $5.00 "on its own" this year.
I think most of the current shareholders expect the share price to go to the .20-.25 range this year with the catalyst(s) being a LymPro partnership and possibly a development partnership for one of the orphan indication for MANF. If both were to happen I think .30 is a possibility.
I expect a 1 for 25 reverse split prior to the uplisting in September or October.
I also expect the share price to be in the .12-.15 range on July 1 as a partnership announcement approaches.
It's fun to speculate. It doesn't cost anything.
Twitter: @AmarantusBio .... 9,970 followers. 10,000 by Friday?
Australian Gold Output Declines After Heavy Rains Lash Mines
http://www.bloomberg.com/news/2014-05-25/australian-gold-output-declines-after-heavy-rains-lash-mines.html?cmpid=yhoo
I thought I was the only one that noticed.
If he's following $AMBS then I expect good things are about to happen.
Twitter: @AmarantusBio .... 9,967 followers.
p.s. Doesn't appear anyone wants to sell shares below .08. I noticed that on Level 2 that there were several large orders for 500,000 shares or more between .07 and .073 the last two trading sessions.
Seems that this isn't going back below .08 on any substantial volume.
I think .10 as the next base is closer than we think.
Twitter: @AmarantusBio .... 9,965 followers.
After it goes above $5.00 on Tuesday ("Wash Rule buyers return) the share price will never go back there.
Should hit the $6.00 area by next Friday with the anticipated upgrades.
Have a great Memorial Day weekend!!!
p.s. Buy/cover before the close today.
I'm expecting upgrades from major brokerages soon. Accumulation of cheap shares continue. Expecting coverage initiation soon with "BUY" ratings and price targets in the $10-$12 range.
Individuals that sold on April 25 can rebuy on Tuesday and under the "wash rule" be able to utilize any losses incurred.
$CYTK is substantially undervalued based on a reasonable assessment of the company's tremendous potential with two partnerships in place and over $1B in milestone payments + royalties expected over the next two years. The company has over $100M in cash on hand and more milestone payments expected.
There is a strong possibility that Cytokinetics will partner with Amgen to move BENEFIT-ALS into phase 3 trials. I think there is also a strong possibility that Amgen will make a buyout offer for Cytokinetics within the next twelve months.
Current fair value is a minimum of $9.00.
All IMHO.
I expect this will be back above $5.00 next week with a nice bounce on Tuesday.
It's oversold and the shorts need millions of shares.
Time will reveal all.
Have a great Memorial Day weekend!!!
BIO International Convention
June 23-26
San Diego,CA
http://mybio.org/exhibitor/member/81245
"Partnering"
Twitter: @AmarantusBio .... 9,964 followers
I don't expect an "ugly" uplist. I expect that from the time the uplist is announced until it happens that the share price will move up 25% or more.
Moving to the NASDAQ is a major positive for the share price.
Time will reveal all.
Twitter: @AmarantusBio .... 9,964 followers.
I expect that several catalysts (including a LymPro partnership) will move the share price to the .25 range by September 1.
The company will announce a 1 for 20 reverse split and will move to the NASDAQ by November 1 with the share price in the $6.00 range.
It is imperative that the company up-lists as soon as possible because with the number of potential catalysts ahead the news of those events shouldn't be wasted because the company is a penny stock trading on the OTC market.
This is probably the best case scenario based on speculation regarding a number of potential catalyst that could realistically occur.
All the talks about the share price going to $2.00 and a reverse split not being needed is "hog wash".
All IMHO.
p.s. If you don't agree that is your choice. That is what makes a market.
Twitter: @AmarantusBio .... 9,964 followers.
After listening to the conference call I would conclude that the bottom is in here. The potential milestone payments and royalties are in excess of $1 billion dollars with the possibility of other partnership to be established.
Anyone who sold on April 25 will be able to buy back in next Tuesday and under the "wash rule" be able to claim the losses that might have resulted from those sales.
Too many potential catalysts to keep the share price so low for much longer. I expect the shorts will start covering as the share price rises and move to stocks with more volatility and more potential to the downside.
Risk/reward favors buying here.
All IMHO.
Cytokinetics Announces Three Publications Relating to Tirasemtiv and the Impact of Skeletal Muscle Activation on Respiratory Function and Muscle Strength
http://finance.yahoo.com/news/cytokinetics-announces-three-publications-relating-113202658.html
New partnership for phase 3 trials?
Stay tuned for news.
Considering the scam stocks you typically follow I'm surprised that found a legitimate one like Amarantus.
Just saying!!!
Looking forward to the conference call tomorrow.
Interesting months ahead.
Access Gerald's B. Riley Investor's Conference presentation at:
http://www.brileyconference.com/2014/register/profile.php?ticker=AMBS
Chance of bankruptcy is higher than ever here. Declining production and increasing production costs are a mix for disaster especially with the price of gold dropping as forecast.
I wouldn't buy GSS here with your money. Much better opportunities in the market.
p.s. Glad you took my advice and got out with a profit. I wish others would have listened. It's much better to sell at .85 than .35.
$6.00 before Wednesday's shareholder's meeting. $8.00 the day after.
GLTA
"Cytokinetics to Hold Annual Meeting of Stockholders"
South San Francisco, CA., May 15, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that its Annual Meeting of Stockholders will be held on Wednesday, May 21, 2014 at 3:00 PM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics` performance.
http://finance.yahoo.com/news/cytokinetics-hold-annual-meeting-stockholders-200202363.html
Buy/cover before the meeting. It's tremendously undervalued.
Might we have an Amgen buyout offer presented at the meeting?
Just saying!!!
This may be the last day below $5.00. Buy/cover before the close today.
GLTA
Thinking Amgen will offer $10.00 knowing that it will be rejected.
Just saying!!!
Accumulation continues by the funds and the brokerages.
Declining daily share volume. Shorts have no ability to take it lower without digging their grave deeper.
Positive news could gap this back above $6.00 at any time with a trend back above $10.00.
"Patience is a virtue."
p.s. If I were Amgen I'd definitely put an offer on the table. Rejection would still bounce the share price.
GLTA
Chart indicates filling the gap to $8.64.
Not if but when. Any positive news gaps this higher.
Under heavy accumulation here. Upgrades to follow:
http://www.theflyonthewall.com/permalinks/entry.php/CYTKid2008668/CYTK-Biotechnology-Value-Fund-reports--passive-stake-in-Cytokinetics
Insiders are buying here:
http://www.americanbankingnews.com/2014/05/12/insider-buying-cytokinetics-director-acquires-10850-shares-of-stock-cytk/
GLTA
Insiders are buying here:
http://www.americanbankingnews.com/2014/05/12/insider-buying-cytokinetics-director-acquires-10850-shares-of-stock-cytk/
Substantially undervalued.
GLTA
Don't be short or on the sidelines when Amgen makes a buyout offer.
It could be detrimental to your profits.
GLTA.
Amgen could buy Cytokinetics using its "petty cash" account.
Amgen Inc. moved into Q2 2014 with $22.81 billion in cash and equivalents on its balance sheet.
In the last year Amgen Inc. invested a reported $9.69 billion in company mergers and acquisitions.
Amgen Owns 4,884,906 Shares of $CYTK. Amgen should make a buyout offer of $7.00/share.
If Amgen offered $7.00 share to buy the company it would cost Amgen approximately $217M to acquire Cytokinetics.
In return Amgen would receive a company with $100M in cash plus approximately $175M in tax-loss carry forward. More importantly Amgen would also save milestone plus royalty payments to Cytokinetics that could exceed $1B. The milestone and royalty payments from Astellas could be worth $300M or more.
The current share price substantially undervalues the company considering the realistic possibility of a takeover offer from Amgen.
Was able to lower my cost basis to $4.09 today. It's great to be "green" finally.
I see lots of "green" ahead as the accumulation continues and positive news from the company and upgrades occur and the share price moves back towards the $10.00 range.
The company has $100M in cash on hand - 22 months of operating capital. Two partnerships in place that could generate $1B in milestone payments plus royalties.
One of the best opportunities in the bio-tech space for a substantial return over the next six months.
"Know what you own."
It wouldn't surprise me if the share price is above $5.00 by next Friday.
Substantially undervalued and oversold here.
Recent buyers will continue to accumulate cheap shares. Major brokerages are getting their clients in here. Upgrades on the horizon.
Substantially oversold with a shrinking float and millions of shares needed to cover as positive news is released.
Needham has a $15.00 price target but I think $10.00 within three months is more realistic.
There's always the possibility that Amgen or Astellas could take a run at buying the company. Sometimes it's better to own than rent.
The game continues.
p.s. The funds that wished they'd bought at $6.00 before it went to $13.00 are taking advantage of the cheap shares. History does tend to repeat.
The Biotechnology Value Fund will probably end up with 10-15% ownership.
Shrinking the float and burning the shorts.
Do you think they're the only fund buying here?
The float is so small here that when the short squeeze begins the share price will move up rapidly as the shorts and flippers chase it.
"Patience is a virtue."
GLTA
Biotechnology Value Fund acquires 6% Passive Stake in Cytokinetics.
http://www.theflyonthewall.com/permalinks/entry.php/CYTKid2008668/CYTK-Biotechnology-Value-Fund-reports--passive-stake-in-Cytokinetics
As I've stated before the accumulation of cheap shares continues. It's only a matter of time before the upgrades occur.
Company has $100M in cash on hand plus the potential for $1B in milestone payments from Amgen and Astellas.
p.s. Don't miss buying/covering at the bottom.
Stock go up and they go down. That's just the way it is.
Even the negative posters don't really think it will stay this cheap.
Hopefully the shorts will continue to short millions of shares under $4.00.
A short squeeze can be fun to watch.
Risk/reward favors buying here.
GLTA
Lowered my average cost down to $4.16 today. Will add a few more shares if it goes below $4.00.
There are too many potential positive catalyst for this to continue much lower.
Amgen has to be considering a bid for the company here. It would be foolish for them not to.
At some point a share buyback program might make sense.
GLTA
Same trading pattern. Move higher expecting "substantive" positive news and when it doesn't happen it sells off.
At least a few flippers are making a dollar or two here.
It could still double/triple at any time.
Twitter: @AmarantusBio .... 9,943 followers.
57 needed to hit 10,000. Remember to "retweet" the company's tweets.